Form 4: Athira Pharma CEO Granted 133,526 Stock Options

Athira Pharma's President and CEO, Mark James Litton, was granted options to purchase 133,526 shares of common stock with an exercise price of $3.81.

Summary

• Mark James Litton, President and CEO of Athira Pharma, Inc. (ATHA), was granted an option to purchase 133,526 shares of common stock.
• The stock option was granted on September 25, 2025, with an exercise price of $3.81 per share, matching the closing price on the Nasdaq Global Market on the grant date.
• The option's vesting is contingent upon the satisfaction of both a milestone requirement and a service-based requirement.
• The milestone requirement was satisfied on December 23, 2025.
• The service-based requirement will vest 50% of the total shares on December 23, 2026, and 1/36th of the remaining 50% on the 23rd day of each month thereafter, subject to continued service.
• The option is exercisable from December 24, 2025, and expires on September 24, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is generally a positive signal, aligning management's interests with shareholders and incentivizing long-term performance. The satisfaction of a milestone requirement is also positive. However, it's a routine compensation disclosure, not a direct operational or financial performance update.

Positives

• The grant of stock options to the CEO aligns management's interests with shareholder value, incentivizing long-term performance and retention.
• A specific milestone requirement for the option's vesting was satisfied on December 23, 2025, indicating progress on a company objective.

Risks

• The full vesting of the stock options is contingent on the CEO's continued service, meaning the benefit is not immediate and could be forfeited if service ceases prematurely.
• The value of the options is directly tied to the future stock performance of Athira Pharma, which is subject to market volatility and inherent risks associated with the biotechnology industry.

Future Outlook

The vesting schedule for the stock options extends through December 23, 2026, and monthly thereafter, indicating a long-term incentive structure for the CEO tied to future company performance and continued service.

Management Comments

• The reporting person was granted an option to purchase 133,526 shares of common stock on September 25, 2025.
• The option was scheduled to vest only upon satisfaction of both a milestone requirement and a service-based requirement.
• The Milestone Requirement was satisfied on December 23, 2025.
• The Service-Based Requirement will be satisfied as to 50% of the total number of shares granted under the option on December 23, 2026, and as to 1/36th of the remaining 50% on the 23rd day of each month thereafter, subject to the optionee continuing to be a Service Provider.

Industry Context

This is a standard insider transaction disclosure for a biotechnology company, reflecting common practices for executive compensation through equity incentives to align leadership with long-term shareholder interests and encourage retention in a competitive industry.

Comparison to Industry Standards

• Granting stock options to executive leadership is a common practice across the biotechnology and pharmaceutical industries to incentivize performance and retention, similar to compensation structures seen at companies like Biogen or Vertex Pharmaceuticals.
• The vesting structure, combining milestone and service-based requirements, is typical for long-term incentive plans in growth-oriented companies like Athira Pharma, ensuring executives are rewarded for both specific achievements and sustained commitment.
• An exercise price equal to the market price on the grant date (at-the-money options) is a standard approach for new grants, ensuring future value creation for the executive is tied directly to stock price appreciation, aligning with best practices for executive equity compensation.

Corporate Governance

Related Party Transactions

• The grant of stock options to Mark James Litton, the President and CEO, constitutes a related party transaction, which is a standard form of executive compensation disclosed transparently through this Form 4 filing.

Stakeholder Impact

• Shareholders: Potential positive impact as the CEO's incentives are aligned with long-term stock price appreciation. There is a potential for future dilution upon exercise of options, which is standard for equity compensation plans.
• Employees: No direct impact on general employees is mentioned, but executive compensation practices can influence overall company culture and morale.

Next Steps

• Continued service by the CEO to meet the service-based vesting requirements for the granted options.
• Future stock price performance of Athira Pharma will determine the ultimate value realized from these options.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to the CEO as part of their compensation package. While it aligns management's interests with shareholders and indicates a milestone was met, it does not provide new operational or financial performance data that would warrant a change in investment recommendation. It's a standard disclosure, suggesting no immediate catalyst for a 'buy' or 'sell' decision based solely on this filing.

Keywords

Athira Pharma, ATHA, Stock Option, Insider Transaction, Form 4, CEO Compensation, Equity Incentive, Mark James Litton, Biotechnology, Pharmaceuticals